SCHEMBL7198230

SCHEMBL7198230

COc1[c]ccc(OC)c1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 5/20 0.39
PDE4A P27815 3/20 0.39
PDE4C Q08493 3/20 0.39
PDE4D Q08499 3/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
FABP3 P05413 1/20 0.38
FABP4 P15090 1/20 0.38
FABP5 Q01469 1/20 0.38
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4439979 0.82 ALDH1A1 (0.42) CA12CA1CA2CA4CA7
SCHEMBL7468941 0.81 PDE4B (0.40) PDE4BPDE4APDE4CPDE4DCA4
SCHEMBL7071376 0.81 PDE4B (0.39) PDE4BPDE4APDE4CPDE4DCA12
SCHEMBL8908078 0.81 CA1 (0.41) CA12CA1CA2CA4CA7
SCHEMBL5676543 0.80 KMT2A (0.40) PDE4BPDE4APDE4CPDE4DCA12
SCHEMBL4843869 0.80 PDE4B (0.38) PDE4BPDE4APDE4CPDE4DCA1
SCHEMBL5982995 0.80 PDE4B (0.38) PDE4BPDE4APDE4CPDE4DCA12
SCHEMBL11100996 0.80 APP (0.47) CA12CA1CA2CA4CA7
SCHEMBL7466427 0.78 APP (0.42) CA12CA1CA2CA4CA7
SCHEMBL7152266 0.77 PDE4B (0.36) PDE4BPDE4APDE4CPDE4DCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6509426-B2 Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability JAPAN POLYCHEM CORPORATION (JP) 2003-01-21 US claimed
US-6509426-B2 Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability JAPAN POLYCHEM CORPORATION (JP) 2003-01-21 US disclosed
US-20010023296-A1 Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer JAPAN POLYCHEM CORPORATION (JP) 2001-09-20 US disclosed
EP-1133475-A1 SUBSTITUTED BENZO DE]ISOQUINOLINE-1,3-DIONES MERCK PATENT GmbH (DE) 2001-09-19 EP disclosed
US-6218558-B1 BRIDGED OXYGEN-, NITROGEN- OR SULFUR-CONTAINING METALLOCENE CATALYST CONTAINING AT LEAST CYCLOPENTADIENE RING FUSED TO A C7-10 RING JAPAN POLYCHEM CORPORATION (JP) 2001-04-17 US disclosed
WO-2000031039-A1 SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES MERCK PATENT GMBH (DE) 2000-06-02 WO disclosed
EP-0963996-A2 Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer Japan Polychem Corporation (JP) 1999-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010023296-A1 Novel transition metal compound, catalyst component for olefin polymerization and process for the preparation of alpha-olefin polymer OSTC, TCP1, COG1 PDE4B 4790/4885PDE4A 4804/4885PDE4C 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.